US-based biotechnology company Cidara Therapeutics has started dosing in its Phase II Radiant clinical trial for its new echinocandin, CD101, to treat acute vulvovaginal candidiasis (VVC).

Cidara’s CD101 is an antifungal drug form belonging to the echinocandin class and has a range of abilities to combat the candida species of fungus.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The multicentre, randomised, open-label, active-controlled, dose-ranging Phase II trial, Radiant will include 125 patients subjected to three forms of CD101.

In the first group of the trial, 50 patients will be applied with the CD101 Ointment.

"Because of their excellent safety record and potency against Candida, echinocandin antifungals are recommended as first line therapy to fight systemic Candida infections."

The next cohort will involve another 50 patients treated with CD101 Gel, while the third will administer 25 patients with oral fluconazole.

See Also:

The trial will focus on a primary endpoint to determine the safety and tolerability of a single dose of CD101 Ointment and multiple doses of CD101 Gel in patients with acute VVC.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The secondary endpoint focuses on determining the therapeutic efficacy of CD101 when administered to patients with acute VVC.

Cidara president and CEO Jeffrey Stein said: "Because of their excellent safety record and potency against Candida, echinocandin antifungals are recommended as first line therapy to fight systemic Candida infections.

"CD101 topical will be the first echinocandin tested clinically in VVC, and we expect to demonstrate a safe and improved eradication of Candida with rapid symptom relief for women seeking a better option over the existing azole class of antifungals."

Last month, Cidara secured the qualified infectious disease product (QIDP) and fast track designation granted by the US Food and Drug Administration (FDA) for its CD101.